Google
×
Past month
  • Any time
  • Past hour
  • Past 24 hours
  • Past week
  • Past month
  • Past year
All results
5 days ago · Background: Allogeneic hematopoietic cell transplantation (allo-HCT) remains an important curative modality for patients with Philadelphia-positive acute ...
3 days ago · High-risk acute myeloid leukemia has been associated with a poor outcome. Hematopoietic stem cell transplantation (HSCT) represents the only curative option ...
Sep 19, 2024 · Allogeneic hematopoietic stem cell transplantation (HSCT) is the only established potentially curative therapy for hematological abnormalities in FA. The ...
Missing: syndromes | Show results with:syndromes
Oct 4, 2024 · myelogenous leukemia: on behalf of the Acute Leukemia Working Party · of the European Society for Blood and Marrow Transplantation. Biol Blood · Marrow ...
Oct 1, 2024 · Promoting access to and excellence in hematopoietic cell transplantation (HCT) by collecting and disseminating data on global HCT activities is one of the ...
Oct 4, 2024 · Allogeneic hematopoietic cell transplantation (allo-HCT) is a potentially curative option for patients with acute leukemia with previous failed treatments (1).
Missing: syndromes | Show results with:syndromes
Sep 28, 2024 · We herein report the results of a large retrospective registry study comparing hematopoietic cell transplantation (HCT) outcomes between double‐unit umbilical ...
Missing: Haematopoietic Leukaemia
Oct 1, 2024 · On the other hand, patients harboring DDX41 PV who undergo hematopoietic stem cell transplantation (HSCT) have high rates of GVHD, the risk of which can be ...
Missing: Haematopoietic | Show results with:Haematopoietic
Sep 24, 2024 · The Myelofibrosis Transplant Scoring System (MTSS) was developed with the specific aim of predicting outcomes after hematopoietic stem-cell transplantation ( ...
Missing: Leukaemia | Show results with:Leukaemia
Sep 14, 2024 · PURPOSE Allogeneic hematopoietic stem-cell transplantation (HSCT) is the only potentially curative treatment for patients with myelodysplastic syndromes (MDS).